Arcus Biosciences, Inc. (RCUS)
USD 15.17
(-5.66%)
USD 15.17
(-5.66%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -340 Million USD | -21.43% |
| 2022 | -280 Million USD | -616.15% |
| 2021 | 54.24 Million USD | 143.67% |
| 2020 | -124.23 Million USD | -40.05% |
| 2019 | -88.7 Million USD | -61.7% |
| 2018 | -54.85 Million USD | -2.65% |
| 2017 | -53.44 Million USD | -193.92% |
| 2016 | -18.18 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -106 Million USD | -562.5% |
| 2024 Q1 | -16 Million USD | 82.42% |
| 2023 Q2 | -83 Million USD | 3.49% |
| 2023 FY | -340 Million USD | -21.43% |
| 2023 Q1 | -86 Million USD | -16.22% |
| 2023 Q3 | -80 Million USD | 3.61% |
| 2023 Q4 | -91 Million USD | -13.75% |
| 2022 Q2 | -68.98 Million USD | -2.68% |
| 2022 Q4 | -74 Million USD | -6.63% |
| 2022 FY | -280 Million USD | -616.15% |
| 2022 Q1 | -67.18 Million USD | -123.88% |
| 2022 Q3 | -69.39 Million USD | -0.6% |
| 2021 Q1 | -72.74 Million USD | -39.87% |
| 2021 FY | 54.24 Million USD | 143.67% |
| 2021 Q2 | -76.13 Million USD | -4.66% |
| 2021 Q4 | 281.26 Million USD | 459.97% |
| 2021 Q3 | -78.13 Million USD | -2.63% |
| 2020 FY | -124.23 Million USD | -40.05% |
| 2020 Q1 | -28.4 Million USD | -62.04% |
| 2020 Q2 | -45.37 Million USD | -59.77% |
| 2020 Q3 | 1.55 Million USD | 103.42% |
| 2020 Q4 | -52.01 Million USD | -3451.29% |
| 2019 Q4 | -17.52 Million USD | 24.61% |
| 2019 Q3 | -23.24 Million USD | 20.27% |
| 2019 Q2 | -29.16 Million USD | -55.33% |
| 2019 Q1 | -18.77 Million USD | -39.22% |
| 2019 FY | -88.7 Million USD | -61.7% |
| 2018 Q3 | -12.14 Million USD | 23.61% |
| 2018 FY | -54.85 Million USD | -2.65% |
| 2018 Q2 | -15.89 Million USD | -19.26% |
| 2018 Q1 | -13.33 Million USD | 0.1% |
| 2018 Q4 | -13.48 Million USD | -11.03% |
| 2017 Q1 | -7.3 Million USD | 0.0% |
| 2017 FY | -53.44 Million USD | -193.92% |
| 2017 Q4 | -13.34 Million USD | 42.32% |
| 2017 Q3 | -23.13 Million USD | -139.38% |
| 2017 Q2 | -9.66 Million USD | -32.38% |
| 2016 FY | -18.18 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ADC Therapeutics SA | -165.98 Million USD | -104.837% |
| Alto Neuroscience, Inc. | -37.8 Million USD | -799.257% |
| Annovis Bio, Inc. | -45.03 Million USD | -654.968% |
| Biohaven Pharmaceutical Holding Company Ltd. | -436.05 Million USD | 22.027% |
| Ginkgo Bioworks Holdings, Inc. | -864.4 Million USD | 60.667% |
| Nuvation Bio Inc. | -99.82 Million USD | -240.606% |
| Nuvation Bio Inc. | -99.82 Million USD | -240.606% |
| Theriva Biologics, Inc. | -21.43 Million USD | -1486.487% |
| Zymeworks Inc. | -138.05 Million USD | -146.282% |